경구 고형 의약품 시장 예측(-2034년) : 제형, 약제 방출, 투여 경로, 치료 영역, 제조 프로세스, 약제 유형, 환자층, 최종사용자, 유통 채널 및 지역별 세계 분석

According to Stratistics MRC, the Global Oral Solid Pharmaceuticals Market is accounted for $585.75 billion in 2026 and is expected to reach $969.41 billion by 2034 growing at a CAGR of 6.5% during the forecast period. Oral solid pharmaceuticals refer to drug formulations administered in solid dosage forms such as tablets, capsules, powders, and granules. These formulations are widely preferred due to their stability, ease of handling, precise dosing, and patient compliance. Manufactured through processes like granulation, compression, and coating, oral solids ensure controlled drug release and bioavailability. They are extensively used across therapeutic areas, ranging from chronic disease management to acute treatments. Advances in formulation technologies, including sustained-release and enteric-coated systems, continue to improve efficacy and safety, making oral solid pharmaceuticals a cornerstone of the global pharmaceutical industry.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The global rise in chronic conditions such as cardiovascular disorders, diabetes, respiratory ailments, and cancer is fueling sustained demand for Oral Solid Pharmaceuticals that enable long-term disease management. Patients requiring daily or frequent medication regimens benefit from the convenience and precise dosing that tablets and capsules offer. Pharmaceutical companies are focusing on developing combination products that simplify complex treatment protocols into single solid dosage units, improving patient adherence. As the global burden of chronic diseases continues to escalate, the need for reliable, scalable, and patient-friendly solid formulations remains a cornerstone of pharmaceutical manufacturing and healthcare delivery worldwide.

Restraint:

Complexity in developing poorly soluble drugs

A significant proportion of new chemical entities emerging from drug discovery pipelines exhibit poor aqueous solubility, posing substantial challenges for Oral Solid Pharmaceuticals development. Formulators must employ advanced technologies such as lipid-based systems, nanomilling, and amorphous solid dispersions to achieve adequate bioavailability, increasing development timelines and manufacturing costs. These technical hurdles can delay product launches and limit the feasibility of solid formulations for certain therapeutic classes. Smaller pharmaceutical companies may lack the specialized equipment and expertise required, potentially restricting their ability to compete in markets dominated by complex drug candidates.

Opportunity:

Expansion of continuous manufacturing technologies

The adoption of continuous manufacturing in Oral Solid Pharmaceuticals production offers transformative opportunities for efficiency, quality, and regulatory compliance. Unlike traditional batch processing, continuous manufacturing integrates real-time monitoring and process analytical technology, enabling faster production cycles, reduced waste, and consistent product quality. Regulatory agencies are encouraging these approaches through streamlined approval pathways. As pharmaceutical companies seek to modernize aging facilities and respond to supply chain vulnerabilities exposed during the pandemic, investment in continuous manufacturing platforms for tablets and capsules is accelerating, creating significant growth opportunities for technology providers and contract manufacturing organizations.

Threat:

Intensifying competition from alternative dosage forms

The growing popularity of alternative drug delivery systems such as orally disintegrating tablets, transdermal patches, injectable biologics, and liquid formulations poses a competitive threat to traditional Oral Solid Pharmaceuticals. Patients seeking greater convenience, faster onset of action, or solutions for swallowing difficulties may prefer these alternatives. Pediatric and geriatric populations, in particular, drive demand for non-solid options. Additionally, the biologic drug revolution favors parenteral delivery, diverting research and development investment away from conventional solid platforms. This shift could erode market share if solid dosage innovation fails to keep pace with evolving patient preferences and therapeutic requirements.

Covid-19 Impact:

The COVID-19 pandemic created both disruptions and opportunities for the Oral Solid Pharmaceuticals market. Initial lockdowns caused supply chain interruptions and reduced outpatient visits, temporarily affecting prescription volumes for chronic medications. However, the rapid development and distribution of oral antivirals for COVID-19 treatment demonstrated the critical role of Oral Solid Pharmaceuticals in pandemic response. The crisis also accelerated digital health adoption, boosting e prescriptions and home delivery of medications. Pharmaceutical companies reinforced supply chain resilience by diversifying manufacturing sites and investing in advanced production technologies, positioning the market for sustained growth in the post-pandemic healthcare landscape.

The Pharmaceutical Companies segment is expected to be the largest during the forecast period

The Pharmaceutical Companies segment is expected to account for the largest market share during the forecast period, driven by the central role these organizations play in drug development, manufacturing, and commercialization. Pharmaceutical companies invest heavily in research and development to create innovative Oral Solid Pharmaceuticals, including fixed-dose combinations and specialty tablets for complex diseases. Their established quality systems, regulatory expertise, and extensive distribution networks enable them to maintain leadership across therapeutic categories. Additionally, the ongoing trend toward in-house manufacturing of high-value solid dosage products ensures that pharmaceutical companies continue to dominate end-user consumption of Oral Solid Pharmaceuticals technologies and services.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Pharmacies segment is predicted to witness the highest growth rate, reflecting the rapid digital transformation of healthcare delivery and consumer preference for convenient medication access. Patients increasingly turn to licensed e pharmacies for home delivery of chronic medications, benefiting from competitive pricing, automatic refills, and discreet service. The pandemic permanently shifted buying habits, with many consumers continuing to prefer online channels even after physical pharmacies reopened. Enhanced regulatory frameworks for telemedicine and e prescribing in major markets further support this channel's expansion. As digital health ecosystems mature, online pharmacies are becoming a preferred distribution route for solid dosage products.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by a well-established pharmaceutical industry, strong healthcare infrastructure, and high patient awareness. The presence of numerous multinational pharmaceutical companies, contract manufacturing organizations, and advanced research institutions drives continuous innovation in solid dosage technologies. Favorable reimbursement policies and widespread adoption of digital health tools support robust prescription drug consumption across the region. Additionally, the aging population and high prevalence of chronic diseases such as cardiovascular conditions and diabetes create sustained demand for Oral Solid Pharmaceuticals, cementing North America's market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid healthcare infrastructure development, expanding pharmaceutical manufacturing capabilities, and growing chronic disease burden. Countries including China, India, and South Korea are emerging as global hubs for solid dosage production, attracting significant investment in modern manufacturing technologies. Government initiatives promoting generic medicines and universal healthcare coverage increase accessibility to essential Oral Solid Pharmaceuticals. Rising disposable incomes and growing patient populations seeking convenient oral therapies further drive market expansion. As multinational pharmaceutical companies expand their footprint in the region, Asia Pacific solidifies its position as the fastest-growing market.

Key players in the market

Some of the key players in Oral Solid Pharmaceuticals Market include Catalent Inc., Lonza Group AG, Recipharm AB, Aenova Group, Thermo Fisher Scientific Inc., Pfizer Inc., Novartis AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Viatris Inc., Sanofi S.A., Abbott Laboratories, Bayer AG, and GlaxoSmithKline plc.

Key Developments:

In March 2026, Catalent announced a global partnership with GelMEDIX for the development and clinical manufacturing of iPSC-derived therapies, utilizing its advanced formulation expertise.

In March 2026, Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc., enhancing its clinical trial services and logistics for solid dosage medications globally.

In November 2025, Partnered with AstraZeneca Pharma India to distribute therapies for Hyperkalaemia, focusing on expanding the reach of critical solid dose treatments in emerging markets.

Dosage Forms Covered:

• Tablets
• Capsules
• Powders & Granules
• Lozenges & Pastilles
• Pellets & Mini-Tablets
• Orally Disintegrating Films
• Other Dosage Forms

Drug Releases Covered:

• Immediate Release
• Modified Release
• Sustained Release
• Extended Release
• Controlled Release
• Delayed Release (Enteric-Coated)
• Targeted Drug Delivery Systems

Route of Administrations Covered:

• Oral
• Buccal
• Sublingual

Therapeutic Areas Covered:

• Cardiovascular Diseases
• Oncology
• Central Nervous System (CNS) Disorders
• Anti-Infectives
• Gastrointestinal Disorders
• Respiratory Diseases
• Metabolic Disorders
• Pain Management
• Other Therapeutic Areas

Manufacturing Process Covered:

• Direct Compression
• Wet Granulation
• Dry Granulation
• Extrusion-Spheronization
• Coating Technologies
• Film Coating
• Sugar Coating
• Enteric Coating

Drug Types Covered:

• Branded Drugs
• Generic Drugs
• Over-the-Counter (OTC) Drugs

Patient Demographics Covered:

• Adult Population
• Pediatric Population
• Geriatric Population

End Users Covered:

• Pharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Research Institutes

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Oral Solid Pharmaceuticals Market, By Dosage Form

• 5.1 Tablets
  • 5.1.1 Immediate Release Tablets
  • 5.1.2 Chewable Tablets
  • 5.1.3 Effervescent Tablets
  • 5.1.4 Enteric-Coated Tablets
  • 5.1.5 Film-Coated Tablets
  • 5.1.6 Orally Disintegrating Tablets
• 5.2 Capsules
  • 5.2.1 Hard Gelatin Capsules
  • 5.2.2 Soft Gelatin Capsules
• 5.3 Powders & Granules
• 5.4 Lozenges & Pastilles
• 5.5 Pellets & Mini-Tablets
• 5.6 Orally Disintegrating Films
• 5.7 Other Dosage Forms

6 Global Oral Solid Pharmaceuticals Market, By Drug Release

• 6.1 Immediate Release
• 6.2 Modified Release
• 6.3 Sustained Release
• 6.4 Extended Release
• 6.5 Controlled Release
• 6.6 Delayed Release (Enteric-Coated)
• 6.7 Targeted Drug Delivery Systems

7 Global Oral Solid Pharmaceuticals Market, By Route of Administration

• 7.1 Oral
• 7.2 Buccal
• 7.3 Sublingual

8 Global Oral Solid Pharmaceuticals Market, By Therapeutic Area

• 8.1 Cardiovascular Diseases
• 8.2 Oncology
• 8.3 Central Nervous System (CNS) Disorders
• 8.4 Anti-Infectives
• 8.5 Gastrointestinal Disorders
• 8.6 Respiratory Diseases
• 8.7 Metabolic Disorders
• 8.8 Pain Management
• 8.9 Other Therapeutic Areas

9 Global Oral Solid Pharmaceuticals Market, By Manufacturing Process

• 9.1 Direct Compression
• 9.2 Wet Granulation
• 9.3 Dry Granulation
• 9.4 Extrusion-Spheronization
• 9.5 Coating Technologies
• 9.6 Film Coating
• 9.7 Sugar Coating
• 9.8 Enteric Coating

10 Global Oral Solid Pharmaceuticals Market, By Drug Type

• 10.1 Branded Drugs
• 10.2 Generic Drugs
• 10.3 Over-the-Counter (OTC) Drugs

11 Global Oral Solid Pharmaceuticals Market, By Patient Demographics

• 11.1 Adult Population
• 11.2 Pediatric Population
• 11.3 Geriatric Population

12 Global Oral Solid Pharmaceuticals Market, By End User

• 12.1 Pharmaceutical Companies
• 12.2 Contract Development & Manufacturing Organizations (CDMOs)
• 12.3 Research Institutes

13 Global Oral Solid Pharmaceuticals Market, By Distribution Channel

• 13.1 Hospital Pharmacies
• 13.2 Retail Pharmacies
• 13.3 Drug Stores
• 13.4 Online Pharmacies

14 Global Oral Solid Pharmaceuticals Market, By Geography

• 14.1 North America
  • 14.1.1 United States
  • 14.1.2 Canada
  • 14.1.3 Mexico
• 14.2 Europe
  • 14.2.1 United Kingdom
  • 14.2.2 Germany
  • 14.2.3 France
  • 14.2.4 Italy
  • 14.2.5 Spain
  • 14.2.6 Netherlands
  • 14.2.7 Belgium
  • 14.2.8 Sweden
  • 14.2.9 Switzerland
  • 14.2.10 Poland
  • 14.2.11 Rest of Europe
• 14.3 Asia Pacific
  • 14.3.1 China
  • 14.3.2 Japan
  • 14.3.3 India
  • 14.3.4 South Korea
  • 14.3.5 Australia
  • 14.3.6 Indonesia
  • 14.3.7 Thailand
  • 14.3.8 Malaysia
  • 14.3.9 Singapore
  • 14.3.10 Vietnam
  • 14.3.11 Rest of Asia Pacific
• 14.4 South America
  • 14.4.1 Brazil
  • 14.4.2 Argentina
  • 14.4.3 Colombia
  • 14.4.4 Chile
  • 14.4.5 Peru
  • 14.4.6 Rest of South America
• 14.5 Rest of the World (RoW)
  • 14.5.1 Middle East
    • 14.5.1.1 Saudi Arabia
    • 14.5.1.2 United Arab Emirates
    • 14.5.1.3 Qatar
    • 14.5.1.4 Israel
    • 14.5.1.5 Rest of Middle East
  • 14.5.2 Africa
    • 14.5.2.1 South Africa
    • 14.5.2.2 Egypt
    • 14.5.2.3 Morocco
    • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

• 15.1 Industry Value Network and Supply Chain Assessment
• 15.2 White-Space and Opportunity Mapping
• 15.3 Product Evolution and Market Life Cycle Analysis
• 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

• 16.1 Mergers and Acquisitions
• 16.2 Partnerships, Alliances, and Joint Ventures
• 16.3 New Product Launches and Certifications
• 16.4 Capacity Expansion and Investments
• 16.5 Other Strategic Initiatives

17 Company Profiles

• 17.1 Catalent Inc.
• 17.2 Lonza Group AG
• 17.3 Recipharm AB
• 17.4 Aenova Group
• 17.5 Thermo Fisher Scientific Inc.
• 17.6 Pfizer Inc.
• 17.7 Novartis AG
• 17.8 Roche Holding AG
• 17.9 Sun Pharmaceutical Industries Limited
• 17.10 Teva Pharmaceutical Industries Ltd.
• 17.11 Dr. Reddy's Laboratories Limited
• 17.12 Viatris Inc.
• 17.13 Sanofi S.A.
• 17.14 Abbott Laboratories
• 17.15 Bayer AG
• 17.16 GlaxoSmithKline plc